CER Daily Newsfeed

Value Viewpoint: February 7, 2025

(2/7, Kimberly Westrich, LinkedIn) comments “On Wednesday, ICER published its Revised Evidence Report assessing the comparative clinical effectiveness and value of suzetrigine for the treatment of acute pain. In the report, ICER rates the evidence for suzetrigine as promising but inconclusive (P/I)...On Thursday this week, ICER published its Draft Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. The report rates the evidence for treatment as promising but inconclusive (P/I).” Full

Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”

(2/7, Mary Caffrey, The American Journal of Managed Care) reports “...[Terra Wonsettler, PharmD, MBA, vice president for pharmacy, Evolent:] As we pan out and look at the United States across other countries on the globe, we in the US far outpace other nations and expect to exceed 20% of our GDP on health care spending over just the next 10 years. Meanwhile, the US also lags on health outcomes. So, with that setting and that foundation, patients also deserve high-value care. Outcomes-based reimbursement can be a healthy tool, aligning the entire health continuum from the start of the drug manufacturer, ultimately to the patient.” Full

Trump is Unlikely to End Medicare Drug Price Talks - Here's What That Means for Patients and Pharma

(2/10, Annika Kim Constantino, CNBC) reports “...Trump will likely make some changes to those price talks, and it may not require help from Congress. Trump could either weaken the negotiations in a way that bodes well for the pharmaceutical industry, or try to achieve even deeper savings for patients and the federal government to outdo his predecessor.” Full

PhRMA Pegs Key Areas To Hike Transparency In Drug Price Negotiations

(2/7, Maaisha Osman, Inside Health Policy) reports “...The pharmaceutical lobby group tells IHP transparency could be improved in the agency's application of the bona fide marketing standard to determine when generic competition is available, selection of therapeutic alternatives, evaluation of real-world evidence, and selection of studies used to determine the maximum fair price for selected drugs.” Subscription Required